Status:
UNKNOWN
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Lead Sponsor:
Ferozsons Laboratories Ltd.
Conditions:
Chronic Stable Angina
Eligibility:
All Genders
25-65 years
Phase:
PHASE4
Brief Summary
This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.
Detailed Description
Stress myocardial perfusion imaging (MPI) is widely used for the diagnosis and risk assessment of patients with known or suspected coronary artery disease (CAD). Also, MPI lends itself to monitoring t...
Eligibility Criteria
Inclusion
- Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes.
- Male and female
- Age 25 to 65 years
- Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards.
- Patient must be able to give voluntary written informed consent.
Exclusion
- Hypertension of \> 170/100 mm of Hg
- Valvular heart disease and cardiomyopathy
- Myocardial infarction in \< 6 months
- Unstable angina
- Congestive cardiac failure
- Severe anemia (Hb 7G/dl)
- Cardiac arrhythmias or II or III degree AV block
- Significant liver or renal dysfunction
- IDDM (Type-1 diabetes mellitus)
- Systolic blood pressure \< 100 mm Hg
- Pregnant and nursing women
- Known hypersensitivity to nicorandil
- On calcium channel blockers
- Patients not eligible for Tc 99m SPECT
- Patients in whom beta blockers are contraindicated
- Geographical inaccessibility for treatment or follow-up evaluations
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01397994
Start Date
September 1 2011
End Date
January 1 2012
Last Update
December 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan, 75850